A low molecular weight PSMA-based fluorescent imaging agent for cancer
- 8 October 2009
- journal article
- research article
- Published by Elsevier in Biochemical and Biophysical Research Communications
- Vol. 390 (3) , 624-629
- https://doi.org/10.1016/j.bbrc.2009.10.017
Abstract
No abstract availableKeywords
This publication has 33 references indexed in Scilit:
- Improved detection of ovarian cancer metastases by intraoperative quantitative fluorescence protease imaging in a pre-clinical modelGynecologic Oncology, 2009
- Multivalent Scaffolds for Affinity Maturation of Small Molecule Cell Surface Binders and Their Application to Prostate Tumor TargetingJournal of Medicinal Chemistry, 2008
- Radiohalogenated Prostate-Specific Membrane Antigen (PSMA)-Based Ureas as Imaging Agents for Prostate CancerJournal of Medicinal Chemistry, 2008
- Synthesis and Evaluation of Technetium-99m- and Rhenium-Labeled Inhibitors of the Prostate-Specific Membrane Antigen (PSMA)Journal of Medicinal Chemistry, 2008
- N-[N-[(S)-1,3-Dicarboxypropyl]Carbamoyl]-4-[18F]Fluorobenzyl-l-Cysteine, [18F]DCFBC: A New Imaging Probe for Prostate CancerClinical Cancer Research, 2008
- Metastatic Brain Tumor Surgery Using Fluorescein Sodium: Technical Notemin - Minimally Invasive Neurosurgery, 2007
- Production of Multimeric Prostate-Specific Membrane Antigen Small-Molecule Radiotracers Using a Solid-Phase 99mTc Preloading StrategyJournal of Nuclear Medicine, 2007
- Vascular Targeted Therapy With Anti–Prostate-Specific Membrane Antigen Monoclonal Antibody J591 in Advanced Solid TumorsJournal of Clinical Oncology, 2007
- Fluorescence-guided surgery with 5-aminolevulinic acid for resection of malignant glioma: a randomised controlled multicentre phase III trialThe Lancet Oncology, 2006
- Relationship between the inhibition constant (KI) and the concentration of inhibitor which causes 50 per cent inhibition (I50) of an enzymatic reactionBiochemical Pharmacology, 1973